Education
About Us
Working with TipRanks
Follow Us
NextCure Inc (NXTC)
NASDAQ:NXTC
NXTC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.66 - $2.57
Previous CloseN/A
Volume33.57K
Average Volume (3M)65.56K
Market Cap
$21.82M
Enterprise Value-$31.31M
Total Cash (Recent Filing)$32.77M
Total Debt (Recent Filing)$3.47M
Price to Earnings (P/E)―
Beta0.84
Next Earnings
May 01, 2025EPS Estimate
-0.34Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.09
Shares Outstanding28,006,683
10 Day Avg. Volume30,114
30 Day Avg. Volume65,561
Standard Deviation0.18
R-Squared0.04
Alpha-0.05
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.60
P/FCF Ratio0.00
Enterprise Value/Market Cap-1.44
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit8.50
Enterprise Value/Ebitda0.54
Forecast
1Y Price Target
$3.00Price Target Upside284.62% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
---
NextCure News
PremiumCompany Announcements
NextCure Advances with New Cancer Drug Application
PremiumCompany Announcements
NextCure Reports Improved Financial Performance and Strategic Focus
PremiumCompany Announcements
NextCure to Discuss Innovative Cancer Therapies
---
Bulls Say, Bears Say
Bulls Say
Drug DevelopmentThe proprietary linker used in LNCB74 may have benefits such as increased payload release in tumor cells and superior serum stability.
Drug SafetyLNCB74 is engineered to minimize uptake and toxicity to immune cells, making it a promising candidate in its class.
Bears Say
Market CompetitionThe B7-H4 ADC landscape is competitive with several other clinical stage players, highlighting the challenges LNCB74 may face.
---
Ownership Overview
―
Insiders
6.80% Mutual Funds
11.26% Other Institutional Investors
78.84% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
NXTC FAQ
What was NextCure Inc’s price range in the past 12 months?
NextCure Inc lowest stock price was $0.66 and its highest was $2.57 in the past 12 months.
What is NextCure Inc’s market cap?
NextCure Inc’s market cap is $21.82M.
When is NextCure Inc’s upcoming earnings report date?
NextCure Inc’s upcoming earnings report date is May 01, 2025 which is in 58 days.
How were NextCure Inc’s earnings last quarter?
Currently, no data Available
Is NextCure Inc overvalued?
According to Wall Street analysts NextCure Inc’s price is currently Undervalued.
Does NextCure Inc pay dividends?
NextCure Inc does not currently pay dividends.
What is NextCure Inc’s EPS estimate?
NextCure Inc’s EPS estimate is -0.34.
How many shares outstanding does NextCure Inc have?
NextCure Inc has 28,006,683 shares outstanding.
What happened to NextCure Inc’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of NextCure Inc?
Currently, no hedge funds are holding shares in NXTC
---
Company Description
NextCure Inc
NextCure, Inc. is a clinical-stage biopharmaceutical company, which engages in discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Its novel FIND-IO discovery technology identifies targets based on immunomodulatory function and on which the company is building a proprietary pipeline of immunomedicines. The company was founded by Michael S. Richman and Lieping Chen in September 2015 and is headquartered in Beltsville, MD.
---
NXTC Stock 12 Month Forecast
Average Price Target
$3.00
▲(284.62% Upside)
Technical Analysis
Best Analysts Covering NXTC
1 Year
1 Year Success Rate
2/12 ratings generated profit
1 Year Average Return
-35.37%
reiterated a buy rating 3 months ago
Copying Edward Tenthoff's trades and holding each position for 1 Year would result in 16.67% of your transactions generating a profit, with an average return of -35.37% per trade.
---